Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20352051 | 0.89 | NR1H2 (0.43) | FPR2KDM4EMAPTTHRBPKM | |
| SCHEMBL1651532 | 0.88 | GPR119 (0.47) | KDM4EMAPTTHRBPKMGPR119 | |
| SCHEMBL2546063 | 0.84 | FPR2 (0.48) | FPR2KDM4EMAPTTHRBPKM | |
| SCHEMBL27591836 | 0.82 | USP19 (0.34) | FPR2 | |
| SCHEMBL189570 | 0.81 | FPR2 (0.51) | FPR2KDM4EMAPTTHRBPKM | |
| SCHEMBL27189395 | 0.81 | FPR2 (0.46) | FPR2KDM4EMAPTTHRBPKM | |
| SCHEMBL30288922 | 0.80 | DRD2 (0.50) | — | |
| SCHEMBL29056036 | 0.80 | FPR2 (0.50) | FPR2KDM4EMAPTTHRBPKM | |
| SCHEMBL412749 | 0.79 | HPGD (0.47) | KDM4EMAPTTHRBPKMGPR119 | |
| SCHEMBL26128387 | 0.79 | HPGD (0.51) | FPR2KDM4EMAPTTHRBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | FPR2 1465/4885KDM4E 2943/4885MAPT 4874/4885 |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | FPR2 357/4885KDM4E 1392/4885MAPT 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.